Professor Tony Blakely, Dr Giorgi Kvizhinadze, Dr Linda Cobiac and Professor Nick Wilson.
In this fourth blog that features the BODE3 Interactive League Table, we look at substantive findings across the interventions (so far) in the league table. We use graphs from the league table to cautiously explore (for fear of over-generalizing) what approaches might typically generate the most health gain and be best value-for-money.
Prof Tony Blakely, Prof Nick Wilson, Dr Giorgi Kvizhinadze, Dr Linda Cobiac
Last week we introduced the concept of league tables to compare interventions. This week we provide a brief ‘user guide’ for our just launched BODE3 Interactive League Table. We walk through how to pull down tables and graphs of health gain (quality-adjusted life-years; QALYs), health system costs and cost effectiveness for 50+ interventions currently in the interactive league table.
Prof. Tony Blakely, Prof. Nick Wilson, Dr. Giorgi Kvizhinadze, Dr. Linda Cobiac
This blog introduces league tables, and more specifically the NZ-specific BODE3 Interactive League Table, for comparing interventions on health gain, cost and cost-effectiveness – and potentially many other things. A league table is a useful tool for researchers and policy-makers to get an informed ‘first impression’ of what are the best health interventions to give further consideration to investing in, or disinvesting in. Continue reading
Dr Andrea Teng, Dr Melissa McLeod, Professor Tony Blakely, Professor Nick Wilson
We have just published a modelling study on stomach cancer prevention in the international journal BMC Infectious Diseases (1). This blog briefly examines how a possible population screening programme, that tests and treats for infection by the bacteria Helicobacter pylori in the stomach, may be a cost-effective way to reduce the stomach cancer burden and ethnic inequalities in stomach cancer incidence and mortality in New Zealand.
Professor Tony Blakely
Keytruda, or pembrolizumab, is a new immune inhibitor drug that appears to have pronounced effectiveness in slowing – even reversing – disease progression in patients with advanced melanoma. It has received much media attention in recent months, and even calls from politicians to over-rule the PHARMAC process (currently PHARMAC do not recommend funding). In this blog I apply our BODE3 rapid cost-effectiveness calculator, and find that Keytruda may well be (just) cost-effective – but with huge uncertainty, and variably by age. This blog closely reflects a Radio New Zealand interview with Wallace Chapman last Sunday.